Abstract
Patients with recurrent and radiation/chemotherapy-resistant gynecological cancer carry a poor prognosis. H101 is a recombinant human type-5 adenovirus (Ad5), in which the E1B and E3 gene have been deleted. Previous studies have shown that H101 has anticancer activity and safety in some solid tumors, but the current evidence regarding the effect of H101 on gynecological oncology remains rare. Therefore, the purpose of this clinical trial is to evaluate the effect and safety of H101 intra-tumor injection combined with or without radiotherapy in refractory/recurrent/metastatic gynecological malignancies, and to further explore the mechanism of H101.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
